Addressing Toxicities in CAR T-Cell Therapy

Author(s):

Kristen M. O’Dwyer, MD ,Aaron Logan, MD, PhD

Panelists discuss future directions and unmet needs for chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory (R/R) B-cell acute lymphocytic leukemia (ALL) as well as risk factors that may predict higher likelihoods of severe cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients undergoing treatment.

EP: 1.Introduction to CAR T-Cell Therapies in R/R ALL

EP: 2.Clinical Trials and Real-World Data on Brexu-Cel

EP: 3.Obe-Cel and MRD Outcomes: Insights and Comparisons

EP: 4.Shifting Treatment Paradigms in R/R ALL

EP: 5.Optimizing Bridging Therapies and Post–CAR T Approaches

Now Viewing

EP: 6.Addressing Toxicities in CAR T-Cell Therapy

EP: 7.Health Care Resource Utilization and Transition of Care

EP: 8.Outpatient CAR T Therapy and Expanding Access

EP: 9.Reflections and Future Directions in R/R ALL

Video content above is prompted by the following:

Dr. O’Dwyer to Dr. Molina: What are future directions or remaining unmet needs for CAR T-cell therapy in R/R B-cell ALL?
Resource links: Roddie C et al. Risk factors associated with sub-optimal outcomes following obe-cel: what we have learned from the FELIX trial. ASH 2024 poster abstract or see Appendix 7
Dr. O’Dwyer to Dr. Molina: As we know, CRS and ICANS are associated with CAR T-cell therapies, Dr Molina: Are there risk factors that can predict those who are at higher risk for developing severe CRS and/or ICANs?

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!